Biology Commons^™

Novel Heterocyclic Arylidene Derivatives As Anticancer Agents Against U87 Human Glioblastoma, Benjamin H. Hiramoto

Honors Theses

The primary objectives of this interdisciplinary study were the synthesis of novel heterocyclic arylidenes and the investigation of their anticancer activity against U87 glioblastoma cell viability. Recently, novel hybrid derivatives have been considered as potential candidates for treating glioblastoma, demonstrating a synergistic anticancer effect in previous studies. 12 heterocyclic arylidenes with various functional groups, including halogens and boronic acid, were produced via a Knoevenagel condensation. These compounds and their starting reagents were then administered to U87 glioblastoma cancer cells at graded concentrations within a 12-well cell viability assay to determine each compound’s lethal concentration 50 (LC50). The LC50 of each …